Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $105
Jefferies Remains a Buy on Gilead Sciences (GILD)
Gilead Sciences Analyst Ratings
Gilead Upgraded to Outperform by Leerink on PreEP Outlook
Leerink Partners Upgrades Gilead Sciences(GILD.US) to Buy Rating, Announces Target Price $96
Leerink Partners Upgrades Gilead Sciences(GILD.US) to Buy Rating, Raises Target Price to $96
Gilead Sciences Analyst Ratings
Solid Investment Potential: Buy Rating for Gilead Sciences Amid Positive Revenue Adjustments and Growth Commitment
Bernstein: First time covering eli lilly and co, gilead sciences and amgen, all with an "outperform large cap" rating.
Gilead Sciences Is Maintained at Outperform by BMO Capital
BMO Capital Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $94
Gilead Sciences Analyst Ratings
Bernstein begins to focus on US pharmaceutical stocks, rating eli lilly and co (LLY.US) and others as "outperforming large cap".
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Jefferies Sticks to Its Buy Rating for Gilead Sciences (GILD)
Morgan Stanley Adjusts Price Target on Gilead Sciences to $84 From $79
Morgan Stanley Remains a Hold on Gilead Sciences (GILD)
Wells Fargo Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $100
Morgan Stanley raised the target price of gilead sciences to $100.
Morgan Stanley raised the target price of gilead sciences to $100.